US FDA Special Protocol Assessment Draft Guidance Adds Biosimilars But Not Much Clarity
This article was originally published in SRA
Revisions proposed by the US Food and Drug Administration to its guidance on special protocol assessments (SPAs) reiterate that the agency is not bound by these agreements on the design and size of clinical trial programs. In addition, they clarify for the first time the situations in which the agency may revoke an agreement.
You may also be interested in...
The meetings are tied to requirements from the 2016 21st Century Cures legislation. They could offer more development certainty for sponsors by allowing informal agreements with the agency on pre- and post-market issues.
Cures legislation offers more development certainty for sponsors by allowing informal agreements with the agency on pre- and postmarket issues.
System needs to be changed to enable US FDA to share COVID-19 application data and inspection reports with other regulatory authorities, stakeholders urge. Merck’s Julie Gerberding and former FDA Commissioner Hamburg criticize company announcement of data via press release prior to submission.